Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis | Zendy

Steven Galetta | Zendy; Clyde Markowitz | Zendy; Andrew G. Lee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis

Author(s) -

Steven Galetta,

Clyde Markowitz,

Andrew G. Lee

Publication year - 2002

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinte.162.19.2161

Subject(s) - glatiramer acetate , multiple sclerosis , medicine , interferon beta 1a , interferon beta , interferon beta 1b , clinical trial , disease , interferon , randomized controlled trial , immunology , physical therapy

Within the past 10 years, several immunomodulatory agents (IMAs) have become available for the treatment of relapsing multiple sclerosis (MS), making therapeutic decisions more complex. We performed a systematic review of the literature to assess the efficacy and safety of these agents on physical, inflammatory, and cognitive measures of disease activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research